Ophthalmologic Manifestations of Kaposi Sarcoma Medication
- Author: Jacqueline Freudenthal, MD; Chief Editor: Hampton Roy, Sr, MD more...
Most ophthalmologists may want to delegate the administration of chemotherapeutic agents to chemotherapists or oncologists. The medical therapy for disseminated Kaposi sarcoma consists of either Adriamycin, bleomycin sulfate, and vinblastine sulfate (ABV) combination or liposomal daunorubicin alone. Liposomal doxorubicin is usually reserved for those patients who fail ABV combination or who are intolerant to ABV therapy. Other second-line therapies include the use of paclitaxel and interferon alfa-n3.
These agents inhibit cell growth and proliferation.
Alkaloid extract of Catharanthus roseus. FDA indications for use of vinblastine are Kaposi sarcoma, choriocarcinoma, histiocytosis X, lymphocytic lymphoma, mycosis fungoides, breast carcinoma, and testicular carcinoma. Mechanism of action is to arrest growing cells in metaphase by inhibiting formation of microtubule assembly during spindle formation. For treatment of Kaposi sarcoma, ABV is conventional combination treatment used. Major route of elimination is through excretion. A small portion is eliminated through urine. Main route of administration is IV.
Cytotoxic glycopeptide extracted from a strain of Streptomyces verticillus. Commonly used in combination with Adriamycin and vinblastine. Inhibits DNA, RNA, and protein synthesis. Major route of elimination is through urine. Serum concentrations may increase in patients with poor creatinine clearance.
Cytotoxic anthracycline extracted from Streptomyces peucetius. Not FDA approved for the treatment of Kaposi sarcoma but often used in combination with bleomycin and vinblastine.
Mechanism of action is by intercalation of anthracycline with DNA. Subsequently, this blocks DNA and RNA polymerases, resulting in the inhibition of cell growth and proliferation. Major route of elimination is via biliary excretion.
Anthracycline antibiotic extracted from S peucetius. Indicated for treatment of Kaposi sarcoma. Liposomal version of daunorubicin greatly enhances functional characteristics of the treatment by decreasing plasma clearance and a smaller volume of distribution. Characteristics translate into longer drug exposure. Daunorubicin is a first-line drug for advanced HIV-Kaposi sarcoma. Not recommended for mild involvement.
Extract of Taxus baccata. Indicated for second-line treatment of AIDS-related Kaposi sarcoma. Mechanism of action is to promote polymerization of microtubules and to inhibit depolymerization. Prevention of microtubule dynamics results in the inability of the cell to undergo mitosis. Major route of elimination is through hepatic clearance. All patients should be premedicated with dexamethasone 10 mg PO 12 h before treatment, diphenhydramine 50 mg IV 30 min prior to treatment, and cimetidine or ranitidine IV 30 min before treatment.
These agents are naturally produced proteins with antiviral, antitumor, and immunomodulatory actions. Alfa, beta, and gamma interferons may be given topically, systemically, and intralesionally.
Derived from pooled units of human leukocytes induced by Sendai virus. Human sources of leukocytes are screened carefully for infectious agents (Sendai virus, HIV-1, HTLV-I, HBV, HSV-1, CMV, and EBV).
FDA indication is for condyloma acuminata. Off-label uses include bladder carcinoma, ovarian epithelial carcinoma, renal carcinoma, chronic active hepatitis, AIDS-related Kaposi sarcoma, chronic myelocytic leukemia, hairy cell leukemia, non-Hodgkin lymphoma, malignant melanoma, multiple myeloma, mycosis fungoides, laryngeal papillomatosis, essential thrombocytosis, and carcinoid tumors.
Interferons are secreted normally by cells in response to viral infections. Binding of interferon to receptors initiates of cascade of events that ultimately involves inhibition of viral replication, suppression of mitosis, and other enhancements to the immune system.
Dose of interferon alfa will vary depending on type and brand chosen. SC route is recommended in those with coagulopathies.
Kaposi M. Idiopathisches multiple Pigment-sarkom der Haut. Arch Dermatol. Syphilol. 1872:4. [Medline].
Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999 Apr 16. 48(2):1-22. [Medline].
Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 1982 Apr. 93(4):393-402. [Medline].
Mowatt L. Ophthalmic manifestations of HIV in the highly active anti-retroviral therapy era. West Indian Med J. 2013. 62(4):305-12. [Medline].
Becker KN, Becker NM. Ocular manifestations seen in HIV. Dis Mon. 2014 Jun. 60(6):268-75. [Medline].
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16. 266(5192):1865-9. [Medline].
Ye F, Zhou F, Bedolla RG, Jones T, Lei X, Kang T, et al. Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2011 May. 7(5):e1002054. [Medline]. [Full Text].
Centers for Disease Control and Prevention. Update: AIDS--United States, 2000. JAMA. 2002 Aug 14. 288(6):691-2. [Medline].
Mansour AM. Adnexal findings in AIDS. Ophthal Plast Reconstr Surg. 1993 Dec. 9(4):273-9. [Medline].
Gigase PL, de Muynck A, de Feyter M. Kaposi's sarcoma in Zaire. IARC Sci Publ. 1984. 549-57. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Ocular adnexal Kaposi's sarcoma in acquired immunodeficiency syndrome. Am J Ophthalmol. 1990 Nov 15. 110(5):500-3. [Medline].
Meyers D. Eye signs that alert the clinician to a diagnosis of AIDS. SADJ. 2005. 60:386-387. [Medline].
Emina MO, Odjimogho SE. Ocular problems in HIV and AIDS patients in Nigeria. Optom Vis Sci. 2010 Dec. 87(12):979-84. [Medline].
[Guideline] Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009 Sep 4. 58:1-166. [Medline]. [Full Text].
Brasnu E, Wechsler B, Bron A, et al. Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol. 2005 Oct. 140(4):746-8. [Medline].
Hummer J, Gass JD, Huang AJ. Conjunctival Kaposi's sarcoma treated with interferon alpha-2a. Am J Ophthalmol. 1993 Oct 15. 116(4):502-3. [Medline].
Qureshi YA, Karp CL, Dubovy SR. Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea. 2009 Sep. 28(8):941-3. [Medline].
Hermans P. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS. Biomed Pharmacother. 1998. 52(10):440-6. [Medline].
Samaniego F, Bryant JL, Liu N, et al. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst. 1999 Jan 20. 91(2):135-43. [Medline].
Simonart T, Noel JC, Andrei G, et al. Iron as a potential co-factor in the pathogenesis of Kaposi's sarcoma?. Int J Cancer. 1998 Dec 9. 78(6):720-6. [Medline].
Hermans P, Clumeck N, Picard O, et al. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. J Hum Virol. 1998 Jan-Feb. 1(2):82-9. [Medline].
Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol. 1995 Aug. 13(8):1966-74. [Medline].
Dugel PU, Gill PS, Frangieh GT, Rao NA. Treatment of ocular adnexal Kaposi's sarcoma in acquired immune deficiency syndrome. Ophthalmology. 1992 Jul. 99(7):1127-32. [Medline].
Korn BS, Park DJ, Kikkawa DO. Intralesional mitomycin-C for the treatment of conjunctival Kaposi sarcoma. Ophthal Plast Reconstr Surg. 2011 Jul-Aug. 27(4):e88-90. [Medline].
Shuler JD, Holland GN, Miles SA, et al. Kaposi sarcoma of the conjunctiva and eyelids associated with the acquired immunodeficiency syndrome. Arch Ophthalmol. 1989 Jun. 107(6):858-62. [Medline].
Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug. 14(8):2353-64. [Medline].
Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997 Feb. 15(2):653-9. [Medline].
Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998 Mar. 16(3):1112-21. [Medline].